Among the emerging trends in AML treatment, several targeted agents, including inhibitors of FLT3 (FLT3i) [36], Bcl-2 [35], and IDH1/2 [157,158], as well as gemtuzumab ozogamicin [159] and CPX351 [160], have radically changed treatment options for AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.